Hims & Hers Health, INC Form 4 insider transactions

Hims & Hers Health, Inc. CEO Andrew Dudum sold 660,000 shares of Class A Common Stock for approximately $33.4 million under a pre-arranged trading plan.

Hims & Hers Health, Inc. Director David B. Wells received a grant of 3,656 Restricted Stock Units, aligning his interests with long-term shareholder value.

Hims & Hers Health, Inc. director Christopher D. Payne was granted 3,656 Restricted Stock Units, aligning his interests with shareholders.

Hims & Hers Health, Inc. Director Andrea G. Perez Garcia was granted 3,656 Restricted Stock Units, aligning her interests with shareholders.

Hims & Hers Health, Inc. Director Delos M. Cosgrove was granted 3,656 Restricted Stock Units, vesting by mid-2026.

Hims & Hers Health, Inc. director Deborah M. Autor received a grant of 3,656 Restricted Stock Units (RSUs) as part of her compensation.

Hims & Hers Health, Inc.'s Chief Medical Officer, Patrick Harrison Carroll, reported a planned sale of 60,000 Class A Common Stock shares and the grant of 3,656 Restricted Stock Units.

Hims & Hers Health, Inc. Director Anja Manuel was granted 3,656 Restricted Stock Units, vesting by June 2026.

Hims & Hers Health, Inc. director Kare Schultz received a grant of 3,656 Restricted Stock Units, aligning interests with shareholders.

Hims & Hers Director Christiane Pendarvis receives 3,656 RSU grant.

Hims & Hers Health, Inc.'s Chief Commercial Officer, Michael Chi, executed stock options and sold a corresponding number of shares under a pre-arranged 10b5-1 trading plan.

Hims & Hers Health, Inc.'s Chief Legal Officer, Soleil Boughton, sold 2,572 shares of Class A Common Stock for $58.7 per share as part of a pre-arranged 10b5-1 trading plan.

Hims & Hers Health, Inc.'s Chief Commercial Officer, Michael Chi, engaged in pre-planned transactions, exercising stock options and selling an equivalent number of Class A Common Stock shares.

Hims & Hers Health, Inc. CEO Andrew Dudum executed a series of stock option exercises and subsequent sales of Class A Common Stock on July 21, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.

Hims & Hers Health, Inc. CEO Andrew Dudum sold 50,326 shares of Class A Common Stock on July 16, 2025, through a pre-arranged Rule 10b5-1 trading plan.

Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc., sold 2,572 shares of Class A Common Stock on July 14, 2025, at $47.82 per share, as part of a pre-arranged Rule 10b5-1 trading plan.

Hims & Hers Health, Inc.'s Chief Financial Officer, Oluyemi Okupe, executed a pre-planned transaction on July 14, 2025, involving the exercise of stock options and the subsequent sale of Class A Common Stock.

Hims & Hers Health, Inc.'s Chief Financial Officer, Oluyemi Okupe, executed a pre-planned transaction involving the exercise of stock options and the subsequent sale of Class A Common Stock on July 7, 2025.

Hims & Hers Health, Inc.'s Chief Legal Officer, Soleil Boughton, has filed a Form 4 disclosing a pre-scheduled sale of 2,572 shares of Class A Common Stock on June 30, 2025, pursuant to a Rule 10b5-1 trading plan.

Hims & Hers Health, Inc.'s Chief Financial Officer, Oluyemi Okupe, sold 23,107 shares of Class A Common Stock for approximately $47.25 per share, executed under a Rule 10b5-1 trading plan.

Hims & Hers Health, Inc.'s Chief Commercial Officer, Michael Chi, reported the exercise of Restricted Stock Units and subsequent sales of Class A Common Stock, primarily for tax obligations and under a pre-arranged trading plan.

Hims & Hers Health, Inc. CEO Andrew Dudum reported significant stock transactions, including the exercise of stock options and sales of Class A Common Stock, primarily conducted under a Rule 10b5-1 trading plan.

Hims & Hers Health, Inc.'s Chief Financial Officer, Oluyemi Okupe, reported the vesting of Restricted Stock Units (RSUs) and a subsequent sale of shares to cover tax obligations, alongside an increase in direct and indirect beneficial ownership.

Hims & Hers Health, Inc.'s Chief Legal Officer, Soleil Boughton, reported the conversion of Restricted Stock Units into Class A Common Stock and subsequent sales of shares totaling over $1.7 million, executed under a pre-arranged 10b5-1 trading plan.

Irene Becklund, an officer at Hims & Hers Health, Inc., reported the vesting of Restricted Stock Units (RSUs) and subsequent sales of Class A Common Stock, including shares withheld for tax obligations, as part of a pre-arranged trading plan.

Michael Chi, Chief Commercial Officer of Hims & Hers Health, Inc., filed an amended Form 4 to correct the reported sale of 5,400 Class A Common Shares on June 10, 2025, at a price of $57 per share.

Christiane Pendarvis, a Director at Hims & Hers Health, Inc., has acquired 9,935 shares of Class A Common Stock through the vesting of Restricted Stock Units, increasing her direct beneficial ownership.

Hims & Hers Health, Inc. Director Christopher D. Payne reported the acquisition of 19,975 shares of Class A Common Stock through the vesting and conversion of Restricted Stock Units on June 12 and June 13, 2025.

Anja Manuel, a Director at Hims & Hers Health, Inc., reported the acquisition of 19,975 Class A Common Stock shares through the vesting of Restricted Stock Units (RSUs) across two transactions in mid-June 2025.

Deborah M. Autor, a Director at Hims & Hers Health, Inc., has acquired 6,175 shares of Class A Common Stock following the vesting of Restricted Stock Units.